Stock CUE CUE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Delayed Nasdaq
Other stock markets
 03:56:20 2024-06-10 pm EDT 		5-day change 1st Jan Change
1.42 USD -4.05% Intraday chart for Cue Biopharma, Inc. -13.33% -45.83%
Jun. 07 Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee CI
May. 09 Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cue Biopharma, Inc. Appoints Michael J. Fox to the Board of Directors and the Compensation Committee
CI
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
GL
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
AQ
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
GL
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
AQ
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
GL
Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
GL
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
GL
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
GL
North American Morning Briefing : Inflation Data, -2-
DJ
Cue Biopharma to Host Business Update Call and Webcast
GL
Cue Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
North American Morning Briefing : Investors -2-
DJ
Jefferies Starts Cue Biopharma With Buy Rating
MT
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CUE Stock
  4. News Cue Biopharma, Inc.